Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients.

abstract：BACKGROUND:Recent randomised trials have demonstrated a statistically significant effect of trastuzumab on disease-free survival when used as adjuvant therapy for human epidermal growth factor receptor 2 protein (HER2)-positive resectable early stage breast cancer, with a treatment course lasting either 9 or 52 weeks. ...

journal_title：PharmacoEconomics

authors： Millar JA,Millward MJ

更新日期：2007-01-01 00:00:00

abstract：:Clinical studies have shown that the combination of an inhaled corticosteroid (ICS) and a long-acting beta(2)-adrenoceptor agonist (LABA) for patients with asthma is more effective than the use of ICS alone in equivalent or higher doses, as well as the use of other combinations. However, the relatively higher acquisit...

journal_title：PharmacoEconomics

authors： Akazawa M,Stempel DA

更新日期：2006-01-01 00:00:00

abstract：:The current US drug innovation financing framework rests on the notion that a defined period of marketing exclusivity combined with the expectation of reimbursement for clinically valuable, cost-effective therapies, followed by vigorous price competition from generic drugs and biosimilars ensures a sufficient return o...

journal_title：PharmacoEconomics

authors： Cutler D,Kirson N,Long G

更新日期：2020-09-01 00:00:00

abstract：:Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...

journal_title：PharmacoEconomics

authors： Husbands S,Jowett S,Barton P,Coast J

更新日期：2017-06-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to estimate the per-patient-per-month (PPPM) costs of medications in the six Medicare Part D protected classes based on findings among Medicare and dual eligible beneficiaries with drug coverage before the enactment of the benefit. DESIGN:Data were from the Thomson Medstat Mar...

journal_title：PharmacoEconomics

authors： Mucha L,Masia NA,Axelsen KJ

更新日期：2006-01-01 00:00:00

abstract：:Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Novosel S,Torrance G,Streiner D

更新日期：1995-07-01 00:00:00

abstract：:It has become increasingly popular to carry out cost-effectiveness analyses in economic evaluations of healthcare programmes. Cost-effectiveness analysis is based on the maximisation of the health effects for a given amount of resources. However, many published studies fail to report the results of cost-effectiveness ...

journal_title：PharmacoEconomics

authors： Karlsson G,Johannesson M

更新日期：1996-02-01 00:00:00

abstract：BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

journal_title：PharmacoEconomics

authors： Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

更新日期：2020-05-01 00:00:00

abstract：:Vaccination is an underutilised, low cost and effective method of preventing illness. Cost-effectiveness analysis discloses a beneficial role of influenza vaccination in preventing illness especially in patients over 65 years of age and in high risk patients. In one large study, when 150 million doses of influenza v...

journal_title：PharmacoEconomics

authors： Perez-Tirse J,Gross PA

更新日期：1992-09-01 00:00:00

abstract：:As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

journal_title：PharmacoEconomics

authors： Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

更新日期：2020-04-01 00:00:00

abstract：:For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

journal_title：PharmacoEconomics

authors： Liljas B,Lindgren B

更新日期：2001-01-01 00:00:00

abstract：:Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability dat...

journal_title：PharmacoEconomics

authors： Ivanova JI,Birnbaum HG,Samuels S,Davis M,Phillips AL,Meletiche D

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To compare the cost effectiveness of sequential intravenous (i.v.) to oral ciprofloxacin plus metronidazole (CIP/MTZ i.v./PO) with that of i.v. ciprofloxacin plus i.v. metronidazole (CIP/MTZ i.v.) and i.v. imipenem-cilastatin (IMI i.v.) in patients with intra-abdominal infections. DESIGN AND PARTICIPANTS:Pat...

journal_title：PharmacoEconomics

authors： Walters DJ,Solomkin JS,Paladino JA

更新日期：1999-11-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：PharmacoEconomics

authors： Paulden M

更新日期：2020-10-01 00:00:00

abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...

journal_title：PharmacoEconomics

authors： Scotland G,Waugh N,Royle P,McNamee P,Henderson R,Hollick R

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:Of 1 346 700 total deaths each year in the US, an estimated 440 100 are smoking related, making it the leading preventable cause of premature death in the US. Despite the health and economic benefits of smoking cessation being well documented, reimbursement coverage for smoking cessation therapies is general...

journal_title：PharmacoEconomics

authors： Howard P,Knight C,Boler A,Baker C

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:To estimate indirect costs in Spanish ambulatory patients with HIV/AIDS and to identify changes in employment status and their current QOL. METHOD:Information was obtained through 32 interviews/enquiries carried out with ambulatory patients receiving medical attention at Gregorio Marañón and Puerta de Hierro...

journal_title：PharmacoEconomics

authors： Oliva J,Roa C,del Llano J

更新日期：2003-01-01 00:00:00

abstract：:Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

journal_title：PharmacoEconomics

authors： Gupta AK

更新日期：1998-02-01 00:00:00

abstract：:Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

journal_title：PharmacoEconomics

authors： Dunn CJ,Goa KL

更新日期：1996-08-01 00:00:00

abstract：:Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

journal_title：PharmacoEconomics

authors： Arguedas MR,Eloubeidi MA

更新日期：2001-01-01 00:00:00

abstract：:Diseases of the prostate currently represent a major health problem worldwide. As the age of the male population increases in the future, so will the number of patients suffering from these disorders and the cost for treatment increase. Currently, benign prostatic hyperplasia (BPH) and prostate cancer are common in ...

journal_title：PharmacoEconomics

authors： Amin EA,Amin M

更新日期：1992-05-01 00:00:00

abstract：:Germany is in a period of transition with regard to healthcare reform. The number and intensity of cost control interventions increased during the last decade in an attempt to contain healthcare expenditure. The German legislature has implemented long term macroeconomic measures such as contribution rate stability and...

journal_title：PharmacoEconomics

authors： Ulrich V,Wille E

更新日期：1996-01-01 00:00:00

abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

journal_title：PharmacoEconomics

authors： Berto P

更新日期：2002-01-01 00:00:00

abstract：:Proper economic evaluation involves comparative analysis of alternative courses of action in terms of both costs and outcome. This is difficult for general anaesthesia as there are few alternatives and measurement of outcome is difficult to define. All that is generally available is a cost description of different a...

journal_title：PharmacoEconomics

authors： Rhodes SP,Ridley S

更新日期：1993-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Accurate prediction of relevant outcomes is important for targeting therapies and to support health economic evaluations of healthcare interventions in patients with diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations are some of the most frequently used risk equation...

journal_title：PharmacoEconomics

authors： Laxy M,Schöning VM,Kurz C,Holle R,Peters A,Meisinger C,Rathmann W,Mühlenbruch K,Kähm K

更新日期：2019-12-01 00:00:00

abstract：:The role of economic evaluation in the efficient allocation of healthcare resources has been widely debated. Whilst economic evidence is undoubtedly useful to purchasers, it does not address the issue of affordability which is an increasing concern. Healthcare purchasers are concerned not just with maximising efficien...

journal_title：PharmacoEconomics

authors： Trueman P,Drummond M,Hutton J

更新日期：2001-01-01 00:00:00

abstract：:Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

journal_title：PharmacoEconomics

authors： Naci H,Fleurence R,Birt J,Duhig A

更新日期：2010-01-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

journal_title：PharmacoEconomics

authors： Cohen BJ

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

journal_title：PharmacoEconomics

authors： Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

更新日期：2019-12-01 00:00:00